Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsALFRY 75 Debt-to-EBITDA is 0.30 as of Mar. 2026, which is 173% above its 10-year median of 0.11. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.25 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 90 Medical Distribution companies, Alfresa Holdings ranks better than 81.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alfresa Holdings's Debt-to-EBITDA or its related term are showing as below:
ALFRY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07 Med: 0.11 Max: 0.65
Current: 0.46
During the past 13 years, the highest Debt-to-EBITDA Ratio of Alfresa Holdings was 0.65. The lowest was 0.07. And the median was 0.11.
ALFRY's Debt-to-EBITDA is ranked better than 81.11% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs ALFRY: 0.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alfresa Holdings Debt-to-EBITDA Related Terms
Alfresa Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Alfresa Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Alfresa Holdings (ALFRY) has a Debt-to-EBITDA of 0.30 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alfresa Holdings. This is 173% above median its historical median of 0.11. Over the past decade, Alfresa Holdings' Debt-to-EBITDA has ranged from 0.07 to 0.65. According to the industry distribution chart, Alfresa Holdings ranks #17 out of 90 companies in the Medical Distribution industry, placing it in the top 18.9%.
Is Alfresa Holdings' Debt-to-EBITDA too high?
Alfresa Holdings' current Debt-to-EBITDA of 0.30 is 173% above median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.65. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Alfresa Holdings' value of 0.30 is 87.8% below this industry median. Based on the distribution chart, Alfresa Holdings ranks #17 out of 90 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #17 out of 90 companies for Debt-to-EBITDA. This places Alfresa Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.45. Alfresa Holdings' value of 0.30 is 87.8% below this benchmark. Historically, Alfresa Holdings' own Debt-to-EBITDA has ranged from 0.07 to 0.65 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 2.45, Alfresa Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current Debt-to-EBITDA of 0.30 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alfresa Holdings. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current Debt-to-EBITDA is 0.30, which is 173% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.25, compared to a current price of $13.55 — trading 16.6% below its estimated fair value. The current Debt-to-EBITDA is 0.30, which is 173% above median its 10-year median of 0.11 and 87.8% below the Medical Distribution industry median of 2.45. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current Debt-to-EBITDA is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.55 is trading 16.6% below its estimated GF Value™ of $16.25.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
Debt-to-EBITDA: 0.30 (173% above median its 10-year median of 0.11)
GF Value™: $16.25 vs. price of $13.55 (16.6% below fair value)
Industry Position: 87.8% below the Medical Distribution median (#17 of 90)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
